StockData
Krystal Biotech, Inc. logo

Krystal Biotech, Inc. (KRYS) stock

KRYSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 11/3052% above fair value
$315.34+16.79 (+5.62%)

Close on Nov 18, 2026Market cap $9.33BP/E 39.5Yield –

Krystal Biotech operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Krystal Biotech's operating income for the twelve months ending Jun 30, 2026 was $197.75M, up 41.8% year over year. For fiscal 2025 it was $161.30M, up 145.3% from the year before. The highest annual figure on record is $161.30M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$161.30M+145.3%
FY2024Dec 31, 2024$65.75M–
FY2023Dec 31, 2023-$109.62M–
FY2022Dec 31, 2022-$145.20M–
FY2021Dec 31, 2021-$68.28M–
FY2020Dec 31, 2020-$33.00M–
FY2019Dec 31, 2019-$22.08M–
FY2018Dec 31, 2018-$11.92M–
FY2017Dec 31, 2017-$4.77M–
FY2016Dec 31, 2016-$1.14M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$58.42M+48.3%
Q1 FY2026Mar 31, 2026$53.69M+48.1%
Q4 FY2025Dec 31, 2025$44.27M+7.0%
Q3 FY2025Sep 30, 2025$41.37M+84.1%
Q2 FY2025Jun 30, 2025$39.40M+359.9%
Q1 FY2025Mar 31, 2025$36.25M–
Q4 FY2024Dec 31, 2024$41.38M+1173.9%
Q3 FY2024Sep 30, 2024$22.47M–
Q2 FY2024Jun 30, 2024$8.57M–
Q1 FY2024Mar 31, 2024-$6.68M–
Q4 FY2023Dec 31, 2023$3.25M–
Q3 FY2023Sep 30, 2023-$25.99M–
Q2 FY2023Jun 30, 2023-$38.05M–
Q1 FY2023Mar 31, 2023-$48.82M–
Q4 FY2022Dec 31, 2022-$34.77M–
Q3 FY2022Sep 30, 2022-$31.45M–
Q2 FY2022Jun 30, 2022-$28.75M–
Q1 FY2022Mar 31, 2022-$50.22M–
Q4 FY2021Dec 31, 2021-$21.88M–
Q3 FY2021Sep 30, 2021-$15.65M–
Q2 FY2021Jun 30, 2021-$16.39M–
Q1 FY2021Mar 31, 2021-$14.35M–
Q4 FY2020Dec 31, 2020-$10.42M–
Q3 FY2020Sep 30, 2020-$9.68M–
Q2 FY2020Jun 30, 2020-$6.95M–
Q1 FY2020Mar 31, 2020-$5.95M–
Q4 FY2019Dec 31, 2019-$6.15M–
Q3 FY2019Sep 30, 2019-$5.34M–
Q2 FY2019Jun 30, 2019-$5.89M–
Q1 FY2019Mar 31, 2019-$4.69M–
Q4 FY2018Dec 31, 2018-$4.22M–
Q3 FY2018Sep 30, 2018-$2.97M–
Q2 FY2018Jun 30, 2018-$2.45M–
Q1 FY2018Mar 31, 2018-$2.28M–
Q4 FY2017Dec 31, 2017-$1.50M–
Q3 FY2017Sep 30, 2017-$2.09M–
Q2 FY2017Jun 30, 2017-$715.00K–
Q1 FY2017Mar 31, 2017-$465.00K–
Q4 FY2016Dec 31, 2016-$620.00K–
Q3 FY2016Sep 30, 2016-$322.00K–

More Krystal Biotech figures

See a number that looks wrong?